Oxford Biomedica plc (LON:OXB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Oxford Biomedica plc (LON:OXB) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 604.32.

Several research analysts have recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a GBX 1,170 target price on shares of Oxford Biomedica in a research report on Wednesday, June 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 950 target price on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a research report on Tuesday, June 2nd.

Oxford Biomedica Price Performance

Shares of OXB opened at GBX 609 on Friday. The firm has a market cap of £736.94 million, a price-to-earnings ratio of -22.62 and a beta of 1.10. The stock has a 50 day moving average of GBX 612.91 and a 200-day moving average of GBX 663.51. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. Oxford Biomedica has a 52 week low of GBX 305.50 and a 52 week high of GBX 952.

Oxford Biomedica (LON:OXB) last issued its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. As a group, analysts forecast that Oxford Biomedica will post -31.0799998 EPS for the current year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.